XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Apr. 30, 2018
Apr. 30, 2017
Operating activities    
Net (loss) income $ (3,336) $ 19,099
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Depreciation and amortization 17,207 16,075
Deferred income taxes 4,524 (14,979)
Provision for doubtful accounts receivable 1,120 433
Realized loss (gain) on marketable securities 16 (331)
Interest in the equity of investments (11) (402)
Stock-based compensation 2,842 2,793
Change in assets and liabilities:    
Restricted cash and cash equivalents (16,562) 3,532
Trade accounts receivable 2,943 (18,883)
Prepaid expenses, other current assets and other assets (13,436) (6,065)
Trade accounts payable, accrued expenses, other current liabilities and other liabilities (21,075) 8,488
Customer deposits 18,468 (2,403)
Deferred revenue (8,138) (6,843)
Net cash (used in) provided by operating activities (15,438) 514
Investing activities    
Capital expenditures (15,969) (17,050)
Proceeds from sale of interest in Straight Path IP Group Holding, Inc. 6,000
Purchase of IP Interest from Straight Path Communications Inc. (6,000)
Payment for acquisition, net of cash acquired (1,827)
Cash used for investments (8,527)
Purchases of marketable securities (22,208) (38,720)
Proceeds from maturities and sales of marketable securities 36,655 30,836
Net cash used in investing activities (1,522) (35,288)
Financing activities    
Dividends paid (11,677) (13,155)
Cash of Rafael deconsolidated as a result of spin-off (9,287)
Distributions to noncontrolling interests (1,023) (1,139)
Proceeds from borrowings under revolving credit facility 22,125
Repayments of borrowings under revolving credit facility (22,125)
Sale of Class B common stock 10,000
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc. 1,000
Proceeds from sale of member interests in CS Pharma Holdings, LLC. 1,250
Proceeds from exercise of stock options 835
Repurchases of Class B common stock (61) (1,838)
Net cash used in financing activities (22,048) (3,047)
Effect of exchange rate changes on cash and cash equivalents (66) (264)
Net decrease in cash and cash equivalents (39,074) (38,085)
Cash and cash equivalents at beginning of period, including $5,716 held for sale at July 31, 2017 96,060 109,537
Cash and cash equivalents at end of period, including $6,833 held for sale at April 30, 2018 56,986 71,452
Supplemental schedule of non-cash investing and financing activities    
Net assets excluding cash and cash equivalents of Rafael deconsolidated as a result of spin-off (105,632)
Reclassification of liability for member interests in CS Pharma Holdings, LLC $ 8,750